Researchers at Johns Hopkins Medicine have discovered that blocking fructose metabolism in a deadly form of childhood brain cancer could help the immune system fight the disease, according to a study published in Acta Neuropathologica Communications. The findings, based on experiments in mice, suggest a new avenue for treating group 3 medulloblastoma, a hard-to-treat pediatric brain tumor with poor survival rates.
The study, conducted at the Kimmel Cancer Center, focused on how tumor cells generate energy. Group 3 medulloblastoma cells rely heavily on fructose as a fuel source. By disrupting this metabolic pathway, the researchers were able to slow tumor growth and boost the immune response against the cancer. This approach could lead to novel therapies that combine metabolic inhibitors with immunotherapy.
Medulloblastoma is the most common malignant brain tumor in children, and group 3 is the most aggressive subtype, with a five-year survival rate of only 50-60%. Current treatments include surgery, radiation, and chemotherapy, which can cause long-term side effects. The new findings offer hope for more targeted, less toxic therapies.
“Our study shows that targeting fructose metabolism can not only impair tumor growth but also make the cancer more visible to the immune system,” said lead researcher Dr. [Name not provided in source]. This dual effect could be key to developing effective immunotherapies for this cancer.
The research aligns with efforts by companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which is developing treatments for glioblastoma and other brain cancers. While CNS Pharmaceuticals focuses on different mechanisms, the Johns Hopkins study underscores the importance of metabolic targeting in brain tumors.
The implications for patients and the broader oncology field are significant. If these findings translate to humans, they could lead to clinical trials combining fructose metabolism inhibitors with existing immunotherapies. This would represent a paradigm shift in treating group 3 medulloblastoma, potentially improving survival and quality of life for affected children.
Further research is needed to identify safe and effective drugs that block fructose metabolism in humans. The Johns Hopkins team plans to explore this pathway in more detail and test combination therapies in preclinical models.
